Beijing Sun-Novo Stock Hits Day High with 8.58% Surge

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. has experienced a significant uptick in its stock performance, gaining 8.58% on March 24, 2026. The stock reached an intraday high of CNY 60.65, marking a notable moment in its trading activity. In terms of performance metrics, the company has shown a year-to-date decline of 2.49%, contrasting with the China Shanghai Composite's slight drop of 2.21%. Over the past year, Beijing Sun-Novo has outperformed the broader market, achieving a return of 39.99% compared to the composite's 15.17%. However, the stock has faced challenges in the short term, with a weekly decline of 4.91% and a monthly drop of 7.94%. Financially, the company operates within the mid-cap pharmaceuticals and biotechnology sector, boasting a market capitalization of CNY 5,405 million. Despite its recent gains, the stock's valuation metrics indicate a price-to-earnings ratio of 48.00 and a price-to-book ratio of 4.65, suggesting a premium valuation relative to its earnings and book value.